Xenetic Biosciences, Inc. filed a current report on Form 8-K with the SEC on September 23, 2026, disclosing the release of an updated investor presentation related to its pending share exchange transaction with Santersus AG.

Key Highlights

  • Updated presentation released: Xenetic released an updated investor presentation on September 23, 2026, in connection with its pending share exchange transaction with Santersus AG.
  • Transaction previously announced: The share exchange transaction with Santersus AG was previously announced on September 16, 2026, according to the filing.
  • Soliciting material designation: The filing is checked as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
  • Proxy and registration filings planned: According to the filing, Xenetic will file a Proxy Statement on Schedule 14A and a Registration Statement on Form S-1 with the SEC in connection with the acquisition.
  • Furnished, not filed: The filing states that the information in Item 7.01, including Exhibit 99.1, "shall not be deemed 'filed' for any purpose."

Xenetic Discloses Updated Presentation Tied to Santersus AG Share Exchange

Xenetic Biosciences, Inc. (NASDAQ:XBIO), incorporated in Nevada and headquartered at 945 Concord Street, Framingham, Massachusetts 01701, filed a current report on September 23, 2026, under Item 7.01 (Regulation FD Disclosure). The filing discloses that the company released an updated investor presentation in connection with its pending share exchange transaction with Santersus AG, a transaction that the filing states was previously announced on September 16, 2026. The updated presentation is attached as Exhibit 99.1.

The filing states that Xenetic intends to file a Proxy Statement on Schedule 14A and a Registration Statement on Form S-1 with the SEC in connection with what it refers to as "the Acquisition." The filing directs investors and security holders to read those documents carefully when they become available, noting they will contain information about the acquisition and the parties involved. Reference is also made to Xenetic's Annual Report on Form 10-K for the year ended December 31, 2025, filed March 12, 2026, and amended April 24, 2026, as a source of additional information about directors, executive officers, and their stock ownership.

The filing notes that it contains "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The company identifies those statements as the views of management and cautions that actual results could differ materially due to factors including the risk that conditions to closing the acquisition are not satisfied, uncertainties as to timing, risks related to operating expenses, and the potential that stockholders could own more or less of the combined company than currently anticipated, among other listed risks.

What Was Disclosed

Xenetic Biosciences filed an 8-K on September 23, 2026, furnishing an updated investor presentation as Exhibit 99.1 under Regulation FD in connection with its pending share exchange transaction with Santersus AG, which was first announced September 16, 2026.